Tiva in MD Anesthesia
Reading File
Finding Sources
Finding Sources
Finding Sources
Reading File
Reading File
Reading File
Reading File
Reading File
Finding Sources
Searching PubMed
"total intravenous anesthesia" AND propofol
Good, I have enough to compose a comprehensive, exam-oriented answer for TIVA. Here it is:
Total Intravenous Anaesthesia (TIVA) — MD Anesthesia Overview
Definition
TIVA is a technique of general anesthesia produced and maintained entirely by intravenously administered drugs, without any inhalational agents (including nitrous oxide) - Miller's Anesthesia, 10e.
Rationale / Advantages
- Avoids airway/environmental pollution and vaporizer needs (useful when inhaled delivery is compromised, e.g. space/austere environments, bronchopleural fistula, malignant hyperthermia risk).
- Smoother emergence with less PONV - propofol has intrinsic antiemetic properties, so propofol-based TIVA is often used specifically in high-risk-PONV patients as part of a multimodal regimen - Morgan and Mikhail's Clinical Anesthesiology, 7e.
- Preferred in malignant hyperthermia-susceptible patients since inhaled agents can trigger life-threatening rhabdomyolysis - Miller's Anesthesia, 10e.
- Rapid, predictable, "trouble-free" emergence when using short-context-half-time drugs like remifentanil.
- Increasingly used in pediatric anesthesia (propofol + remifentanil being the dominant protocol), though a recognized limitation in children is the lack of a validated depth-of-anesthesia monitor.
Core pharmacological principle: Context-Sensitive Half-Time (CSHT)
The key concept that makes rational TIVA possible is CSHT - the time for plasma drug concentration to fall by 50% after stopping an infusion of a given duration. Propofol has a comparatively short CSHT that increases only minimally with infusion duration, making it the preferred hypnotic for prolonged infusions, unlike thiopental whose CSHT rises steeply - Barash, Cullen & Stoelting's Clinical Anesthesia, 9e; Katzung's Basic and Clinical Pharmacology.
Standard drug combinations
| Component | Common agents | Typical dosing |
|---|---|---|
| Hypnotic | Propofol | Induction 0.5-1.5 mg/kg (or TCI); maintenance 80-120 mcg/kg/min (~4-12 mg/kg/h) |
| Opioid | Remifentanil, alfentanil, sufentanil, fentanyl | Remifentanil infusion 0.1-1.0 mcg/kg/min; alfentanil 25-50 mcg/kg bolus + 0.5-1.5 mcg/kg/min; sufentanil bolus 0.1 mcg/kg + 0.005-0.03 mcg/kg/min |
Propofol and opioids act synergistically (pharmacodynamic synergism): fentanyl markedly reduces the propofol concentration needed to prevent response to noxious stimuli (Kazama's CP50 studies), and response-surface analysis shows strong synergy between propofol and remifentanil for both sedation and suppression of noxious responses - Miller's Anesthesia, 10e (Ch. 22).
Remifentanil-propofol TIVA gives faster respiratory recovery than alfentanil-propofol TIVA after brief procedures. A caveat: high-dose remifentanil can cause opioid-induced hyperalgesia on discontinuation, so alternative postoperative analgesia must be planned in advance.
Delivery methods
- Manual/weight-based infusion - bolus + fixed continuous infusion, adjusted clinically.
- Target-Controlled Infusion (TCI) - pharmacokinetic-pharmacodynamic (PK-PD) model-driven pumps that target a desired plasma or effect-site concentration; this is the recommended method for propofol maintenance per the 2019 Association of Anaesthetists/Society for Intravenous Anaesthesia guidelines - Miller's Anesthesia, 10e.
- Advanced displays (e.g., "Medvis") show real-time and predicted effect-site concentrations for sedation, analgesia, and muscle relaxation with population-based probability curves (e.g., probability of unconsciousness, no response to intubation, no TOF twitch).
Monitoring during TIVA
- Because there's no end-tidal agent concentration to gauge depth (unlike volatile anesthesia), processed EEG monitoring (e.g., BIS) is important and is specifically recommended whenever a neuromuscular blocking drug is co-administered with TIVA, to reduce awareness risk.
- Standard ASA monitoring plus vigilance for IV line patency (cannula should be visible whenever practical) - occult extravasation causes awareness due to unrecognized under-dosing.
Safety recommendations (2019 AAGBI/SIVA guidelines, reproduced in Miller's)
- All anesthetists should be trained and competent in TIVA delivery.
- Use TCI for propofol maintenance; start with lower target concentrations in elderly/frail patients.
- Standardize propofol concentration and dilute remifentanil to one standard concentration departmentally.
- Infusion sets need Luer-lock connectors, anti-syphon valve on drug line(s), anti-reflux valve on fluid line, with drug/fluid junctions as close to the patient as possible to minimize dead space.
- Program pumps only after the syringe is loaded.
- Same monitoring standards apply even when TIVA is used outside the operating room (e.g., ICU, radiology suite).
Clinical applications
- ENT/ophthalmic/neurosurgery (reduces PONV, stable hemodynamics, useful when muscle relaxant monitoring/EEG needed without volatile confound)
- Cardiac anesthesia - modern practice has shifted from pure high-dose opioid techniques (fentanyl 50-100 mcg/kg) toward TIVA with short-acting agents or combined IV-volatile "balanced" techniques, since pure high-dose opioid anesthesia caused prolonged postoperative respiratory depression and increased awareness risk - Morgan & Mikhail, 7e.
- Malignant hyperthermia-susceptible patients
- Space/military/austere environments where scavenging volatile agents is impractical
- Pediatric anesthesia (propofol-remifentanil)
Disadvantages / pitfalls
- No exhaled-gas concentration to confirm delivery - risk of awareness if IV access fails or pump malfunctions (this drove the 2019 safety guidelines).
- Requires infusion pump expertise and PK-PD model literacy (for TCI).
- Cost of propofol/remifentanil and pump equipment.
- Postoperative hyperalgesia with high-dose remifentanil.
- Limited depth-of-anesthesia monitors validated in children.
Recent evidence (last 2 years)
Systematic reviews/meta-analyses comparing TIVA vs inhalational anesthesia continue to be published - e.g. in liver surgery (PMID: 40023497, 2025) and transsphenoidal pituitary surgery (PMID: 40704476, 2025) looking at postoperative recovery outcomes, and a 2024 meta-analysis comparing remimazolam-based TIVA vs propofol-based TIVA for subjective quality of recovery (PMID: 39289773) - reflecting growing interest in remimazolam as an emerging TIVA hypnotic alternative to propofol. These don't overturn the core textbook principles above but are worth reviewing if you need the latest comparative outcome data for exam viva or literature-based questions.
If you want, I can go deeper into any specific sub-topic (TCI pharmacokinetic models like Marsh/Schnider/Minto, propofol infusion syndrome, TIVA in specific special populations, or a comparison table of TIVA vs balanced/inhalational anesthesia) - just let me know which angle you need for your MD prep.
This is a shared conversation. Sign in to Orris to start your own chat.